Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium.

Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman AB

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Apr 2007Cited by 170 (Europe PMC)

PMID17227219DOI10.1359/jbmr.070104PepBankPUB-17227219

Publisher page PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialMechanism
In women with osteoporosis, teriparatide increased cancellous bone formation rate by a factor of 4.5 versus controls.
In plain wordsTeriparatide increased cancellous bone formation compared with control women with osteoporosis.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCancellous bone formation rate
Study
n = 40
Comparator
Untreated control women
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 microg daily · subcutaneous · 1 monthAs given in this study (human).
Measurements
Cancellous bone formation rate ratio
4.5 fold
teriparatide-treated vs control women, cancellous surface
Source sentences
Summary
The bone formation rate on the cancellous and endocortical surfaces was higher in hPTH(1-34)-treated women than in control women by factors of 4.5 and 5.0, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Tetracycline-labeled iliac crest bone biopsies were obtained from 27 postmenopausal women with osteoporosis who were treated for 1 month with hPTH(1-34), 50 microg daily subcutaneously.
Summary · context
The results were compared with tetracycline-labeled biopsies from a representative control group of 13 postmenopausal women with osteoporosis.
Report a problemFND-1722721901
02HumanNon-randomized trialMechanism
In women with osteoporosis, teriparatide increased endocortical bone formation rate by a factor of 5.0 versus controls.
In plain wordsTeriparatide increased endocortical bone formation compared with control women with osteoporosis.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseEndocortical bone formation rate
Study
n = 40
Comparator
Untreated control women
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 microg daily · subcutaneous · 1 monthAs given in this study (human).
Measurements
Endocortical bone formation rate ratio
5 fold
teriparatide-treated vs control women, endocortical surface
Source sentences
Summary
The bone formation rate on the cancellous and endocortical surfaces was higher in hPTH(1-34)-treated women than in control women by factors of 4.5 and 5.0, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Tetracycline-labeled iliac crest bone biopsies were obtained from 27 postmenopausal women with osteoporosis who were treated for 1 month with hPTH(1-34), 50 microg daily subcutaneously.
Summary · context
The results were compared with tetracycline-labeled biopsies from a representative control group of 13 postmenopausal women with osteoporosis.
Report a problemFND-1722721902
03HumanNon-randomized trialMechanism
In women with osteoporosis, teriparatide increased periosteal bone formation rate fourfold versus controls.
In plain wordsTeriparatide increased bone formation on the outer bone surface compared with control women.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePeriosteal bone formation rate
Study
n = 40
Comparator
Untreated control women
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 microg daily · subcutaneous · 1 monthAs given in this study (human).
Measurements
Periosteal bone formation rate ratio
4 fold
teriparatide-treated vs control women, periosteal surface
Source sentences
Summary
We also showed a 4-fold increase in bone formation rate on the periosteal surface, suggesting that hPTH(1-34) has the potential to increase bone diameter in humans.
2 context sentences(design, population, supporting numbers)
Summary · context
Tetracycline-labeled iliac crest bone biopsies were obtained from 27 postmenopausal women with osteoporosis who were treated for 1 month with hPTH(1-34), 50 microg daily subcutaneously.
Summary · context
The results were compared with tetracycline-labeled biopsies from a representative control group of 13 postmenopausal women with osteoporosis.
Report a problemFND-1722721903
04HumanNon-randomized trialMechanism
In women with osteoporosis, teriparatide mainly stimulated cancellous and endocortical formation in ongoing remodeling units.
In plain wordsTeriparatide mainly stimulated formation in active bone remodeling sites in women with osteoporosis.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFormation in ongoing remodeling units
Study
n = 40
Comparator
Untreated control women
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 microg daily · subcutaneous · 1 monthAs given in this study (human).
Source sentences
Summary
On the cancellous and endocortical surfaces, the increased bone formation rate was primarily caused by stimulation of formation in ongoing remodeling units, with a modest amount of increased formation on previously quiescent surfaces.
2 context sentences(design, population, supporting numbers)
Summary · context
Tetracycline-labeled iliac crest bone biopsies were obtained from 27 postmenopausal women with osteoporosis who were treated for 1 month with hPTH(1-34), 50 microg daily subcutaneously.
Summary · context
The results were compared with tetracycline-labeled biopsies from a representative control group of 13 postmenopausal women with osteoporosis.
Report a problemFND-1722721904
05HumanNon-randomized trialMechanism
In women with osteoporosis, teriparatide modestly increased cancellous and endocortical formation on previously quiescent surfaces.
In plain wordsTeriparatide modestly increased formation on previously inactive bone surfaces in women with osteoporosis.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFormation on previously quiescent surfaces
Study
n = 40
Comparator
Untreated control women
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 microg daily · subcutaneous · 1 monthAs given in this study (human).
Source sentences
Summary
On the cancellous and endocortical surfaces, the increased bone formation rate was primarily caused by stimulation of formation in ongoing remodeling units, with a modest amount of increased formation on previously quiescent surfaces.
2 context sentences(design, population, supporting numbers)
Summary · context
Tetracycline-labeled iliac crest bone biopsies were obtained from 27 postmenopausal women with osteoporosis who were treated for 1 month with hPTH(1-34), 50 microg daily subcutaneously.
Summary · context
The results were compared with tetracycline-labeled biopsies from a representative control group of 13 postmenopausal women with osteoporosis.
Report a problemFND-1722721905
06HumanNon-randomized trialMechanism
In women with osteoporosis, teriparatide-stimulated bone formation was associated with increased osteoblast apoptosis.
In plain wordsBone formation during teriparatide treatment was linked to more bone-forming cell death in women with osteoporosis.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseOsteoblast apoptosis
Study
n = 40
Comparator
Untreated control women
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 microg daily · subcutaneous · 1 monthAs given in this study (human).
Source sentences
Summary
hPTH(1-34)-stimulated bone formation was associated with an increase in osteoblast apoptosis,
2 context sentences(design, population, supporting numbers)
Summary · context
Tetracycline-labeled iliac crest bone biopsies were obtained from 27 postmenopausal women with osteoporosis who were treated for 1 month with hPTH(1-34), 50 microg daily subcutaneously.
Summary · context
The results were compared with tetracycline-labeled biopsies from a representative control group of 13 postmenopausal women with osteoporosis.
Report a problemFND-1722721906

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.